Tropicann Jamaica, Weekend Unlimited Acquisition Target, Provides Update on Property Development and Production
Weekend Unlimited Inc. (CSE:YOLO) (FSE:0OS1) (“Weekend” or the “Company”), announces that it’s previously announced acquisition target, R & D Pharma in Jamaica, has advanced its breeding program in anticipation of further expansion.
The R & D Pharma property, branded Tropicann Jamaica, comprises 98-acres, 60-acres of which are usable for cultivation. Currently there are 5.2-acres of terraced outdoor cultivation being used. This includes 3.2-acres of commercial cultivation which is capable of producing 5,750 kg of dry material per year. The remaining 2-acres is used for research and development, producing 3,000 kg. An additional 5-acre outdoor plot is set to be prepared for cultivation commencing in 2019, which should triple production.
The site has a 6,000 sqft. greenhouse which includes a 1,000 sqft. mother room, 400 sqft. stacked clone room, 1000 sqft. veg room and 3,600 sqft. flower room (2500 sqft. of which is canopy), which has the capacity to produce 600 kg of dry material per year for the fully owned on-site dispensary, which is planned to serve the tourism market.
“Currently, the site is in production with 13 acclimated strains & 120 mother plants,” said Mr. Cody Corrubia, Weekend Unlimited Inc. President and CEO. “Another 37 strains are being cultivated and ‘phenotyped’ as a part of an in-depth program to produce unique equatorial and tropical cannabis varieties for both medical and recreational markets,” added Mr. Corrubia.
For further information, please contact:
Mr. Cody Corrubia, President and CEO
Telephone: 1 (236) 317-2812 – Toll free 1(888) 556-YOLO (9656)
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.